Ipsen SA (OTCMKT: IPSEY, IPSEF, Euronext: IPN) was founded in 1929 and is headquartered in Boulogne-Billancourt, France. It has 5,185 full-time employees. It is a French pharmaceutical company that mainly develops and sells cancer (oncology) ), drugs for endocrine diseases and neuromuscular diseases, a subsidiary of Mayroy SA.
Ipsen SA (IPSEY) US stock:
Ipsen Group is an international pharmaceutical company focused on specialized disease treatment. The group has been committed to becoming a leader in providing specialized treatment solutions in the field of target diseases, with sales exceeding 1.4 billion euros in 2015. The group’s business development strategy is supported by four target disease areas, including:
The field of neurology represented by Dysport®; endocrinology represented by Somatuline®; urinary oncology represented by Decapeptyl®; and the field of hematology.
More importantly, the Ipsen Group has always followed an active partnership policy, and its R&D has always focused on innovative and diversified patient-oriented peptide and protein engineering technology platforms. In 2015, Ipsen’s R&D efforts The total expenditure accounts for approximately 13% of the total sales of the entire group, nearly 200 million euros.
Ipsen Group’s shares are traded on the Euronext A market in Paris (stock code: IPN, International Securities Identification Number: FR0010259150), which meets the deferred settlement (“SRD”) standard and is the French stock market index SBF120 One of the important parameters. Ipsen Group implements the U.S. Tier 1 Participating Depository Receipt (ADR) system and trades in the U.S. OTC Market under the IPSEY code.
Ipsen Group provides urology, oncology, endocrinology, neurology, gastroenterology, cognitive impairment, rheumatism and cardiovascular drugs. include:
- Decapeptyl (approved for marketing in the European Union in October 2016)-a synthetic hormone made from triptorelin and gonadotropin releasing hormone decapeptide analogs, used to treat advanced metastatic prostate cancer, uterine fibroids, Precocious puberty, endometriosis and female infertility;
- Hexvix -a photosensitizer for the detection and removal of non-invasive bladder cancer;
- Somatuline -normal saline, used for injectable treatment of acromegaly and neuroendocrine tumors;
- NutropinAq -a liquid preparation used to treat growth disorders (short stature) in adults caused by growth hormone deficiency in childhood;
- Increlex -a long-term therapeutic preparation for the treatment of growth disorders caused by severe primary insulin growth factor 1 deficiency in children and adolescents;
- Dysport -a botulinum toxin type A complex for the treatment of cervical dystonia, cerebral palsy, blepharospasm and hemifacial spasm;
- Smecta -a preparation used to treat chronic and acute diarrhea;
- Forlax -a drug based on linear polyethylene glycol polymers used to treat constipation;
- Tanakan -used to treat age-related cognitive impairment;
- Nisis and Nisisco -antihypertensive drugs for the treatment of hypertension;
- Adenuric -used to treat gout;
- Adrovance -used to treat postmenopausal osteoporosis;
- In addition, Ipsen is developing chimeric somatostatin and dopamine agonist molecules, including: BN82451, VSN16R, OPS201, OPS202, MCNA, and LX1032.
As of December 31, 2016, Ipsen Group products have been sold to 116 countries around the world. Among them, the United States is the country with the largest business and sales, with 300 employees and sales of 158 million euros.